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Abstract  
 
Approximately 15 % of colorectal cancers exhibit instability of short nucleotide repeat regions, 
microsatellites. These tumors display a unique clinicopathologic profile and the microsatellite 
instability status is increasingly used to guide clinical management as it is known to predict 
better prognosis as well as resistance to certain chemotherapeutics. A panel of five repeats 
determined by the National Cancer Institute, the Bethesda panel, is currently the standard for 
determining the microsatellite instability status in colorectal cancer. Recently, a 
quasimonomorphic mononucleotide repeat 16T/U at the 3′ untranslated region of the Ewing 
sarcoma breakpoint region 1 gene was reported to show perfect sensitivity and specificity in 
detecting mismatch repair deficient colorectal, endometrial, and gastric cancers in two 
independent populations. To confirm this finding, we replicated the analysis in 213 
microsatellite unstable colorectal cancers from two independent populations, 148 
microsatellite stable colorectal cancers, and the respective normal samples by PCR and 
fragment analysis. The repeat showed nearly perfect sensitivity for microsatellite unstable 
colorectal cancer as it was altered in 212 of the 213 microsatellite unstable (99.5 %) and none 
of the microsatellite stable colorectal tumors. This repeat thus represents the first potential 
single marker for detecting microsatellite instability.  
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Introduction  
 
Colorectal cancer (CRC) is the third most common cancer in Western countries with a mortality 
rate of nearly 50 % [1]. Approximately 15 % of CRCs display microsatellite instability (MSI) 
as a result of defected mismatch repair (MMR) machinery, which leads to excessive 
accumulation of small insertions and deletions [2]. These most often target short repeat regions 
of the genome, microsatellites.  
Over 90 % of MSI CRCs are sporadic [3]. Lynch syndrome, a hereditary cancer predisposition 
syndrome arising due to germline mutations in DNA MMR genes (MLH1, MSH2, MSH6, and 
PMS2) accounts for approximately 2–7 % of MSI CRCs [4]. MSI is also observed in 10–20 % 
of sporadic endometrial and gastric cancers [5].  
MSI CRCs are known to arise through a distinct genetic pathway as compared to microsatellite 
stable (MSS) CRCs [2]. They also display a unique clinicopathologic profile, and thus the MSI 
status is increasingly used to guide clinical management. A large number of genetic loci 
recurrently affected by MSI have been reported [6]. Currently, the analysis of five 
microsatellite markers, the Bethesda panel, is the standard method for determining MSI in CRC 
according to the instructions of the National Cancer Institute Workshop in 1997 [7].  
Recently, a quasimonomorphic mononucleotide T/U16 (EWST16) repeat at the 3′ untranslated 
region (UTR) of Ewing sarcoma breakpoint region 1 (EWSR1) was reported by Kishore et al. 
to show perfect sensitivity and specificity in detecting MMR deficient cancers in two 
independent populations [8]. The first sample set consisted of 85 Swiss Lynch syndrome- 
related cancers and 113 sporadic CRCs, and the second set of eight Finnish Lynch syndrome-
related cancers, 50 sporadic CRCs as well as 64 sporadic gastric cancers. The locus does not 
affect the protein coding sequence of EWSR1 but was shown to associate with changes in the 
expression and subcellular localization of the encoded protein.  
Here, we analyzed the EWS16T locus in 213 MSI (157 Finnish and 56 Danish) 148 MSS 
(Finnish) CRCs, and corresponding normal samples. The repeat showed nearly perfect 
sensitivity for MSI CRC: it was mutated in 212 out of 213 (99.5 %) MSI tumors while all the 
148 MSS tumors were wild type. Our results are similar to those of Kishore and co-workers 
and support the utility of the repeat as an effective marker for detecting MSI status.  
Materials and methods  
Study subjects  
A series of 157 MSI CRCs and 148 MSS CRCs were derived from a previously characterized 
population-based series of 1042 Finnish CRCs and an additional series of approximately 1000 
unselected CRCs [9–11]. All tumor DNAs were extracted from histologically evaluated fresh-
frozen tissue. Thirty one of the tumors were from Lynch syndrome patients. Normal tissue 
samples were available from all patients and DNA was extracted either from blood or normal 
colonic epithelium distant from the site of the tumor. Additional 56 Danish MSI CRCs and 
their corresponding normal samples were also available for analysis. The tumor DNA of these 
samples was extracted from gross dissected cancer tissue with the Genetra Puregene DNA 
purification kit (Qiagen, Limburg, The Netherlands).  
 
MSI status determination  
For the samples derived from the set of 1042 CRCs, the MSI status was determined by 
radioactive labeling techniques, fluorescence-based PCR methods or fragment analysis in 
previous studies between 1993 and 1999 [9,10].  
In the radioactive labeling techniques, seven markers (D5S404, D17S787, D5S346, D1S216, 
D11S904, D10S197, and TP53) were analyzed by two reviewers. A sample was called MSI if 
2/7 markers showed instability. If none of the markers showed instability, the sample was 
called MSS, as long as at least 5/7 markers were successfully analyzed. If 1/7 markers showed 
instability, more markers (DCC, D13S175, D7S519, D20S100, D15S120, D2S136, and 
D14S79) were analyzed so that in total at least ten markers were reviewed. If at least one of 
the extra markers showed instability, the sample was called MSI. If none of the markers 
exhibited instability, the sample was called MSS.  
In cases where a fluorescence-based PCR method was used, 16 markers (D8S254, MYC, 
NM23, D5S346, TP53, D1S228, D8S261, D7S496, D8S137, DCC, D7S501, MCC, D5S318, 
D1S507, D19S394, and RB1) were tested for. If at least 30 % of the alleles exhibited instability, 
the sample was called MSI. Later, two markers (BAT26 and TGFBRII) were used. Both 
markers were evaluated by two independent reviewers. If BAT26 showed deletions, the result 
was compared to that of the normal sample to ensure the change was somatic in origin.  
For the samples derived from the latter set of 1000 CRCs, the Bethesda panel of five markers 
(BAT25, BAT26, D5S346, D17S250, and D2S123) was analyzed by fragment analysis [7]. If 
at least 2/5 markers showed instability, the sample was called MSI.  
For the 56 Danish MSI CRCs and corresponding normal samples, MSI status was determined 
by pentaplex polymerase chain reaction with five quasimonomorphic mononucleotide repeats 
(BAT25, BAT26, and three poly(T) tract segments of the following genes: SLC7A8 (NR-21, 
21T), transmembrane precursor protein B5 (NR-22, 22T), and zinc finger-2 (NR-24, 24T) [12]. 
If at least two markers showed instability, the sample was called MSI.  
In previous studies, if a sample derived from the set of 1042 CRCs showed MSI, Sanger 
sequencing of MLH1 and MSH2 was performed [9,10]. For the latter sample set, MMR gene 
mutation data was obtained from diagnostic laboratories [11].  
Fragment analysis  
In this study, the 3′-UTR poly T tract in EWSR1, (g.2608_2624 containing a 16T repeat, 
GRCh38, www.ensembl.org) amplified by PCR with the following primers: 5′-
AATGTTCATGGTTGTGATGT-3′ (forward FAM-labeled) and 5′-
GAAGGATGACTCTTTATAA-3′ (reverse) [8]. The PCR mix contained 
1.5 μl of 1 × PCR-buffer (Applied Biosystems, Brachburg, NJ, USA), 0.2 μl of 
deoxynucleotide triphosphate (dNTP) (FINNZYMES, Espoo, Finland), ® 0.6 μl of forward 
and reverse primer (SIGMA , GENOSYS, Helsinki, Finland), 0.15 μl of DNA polymerase 
enzyme AmpliTaqGold
® 
(Applied Biosystems, Brachburg, NJ, USA), 9.95 μl of water, and 
25 ng of DNA extracted from fresh-frozen colorectal tumor. The PCR program consisted of 
five steps: (1) denaturing at 95 °C for 10 min, (2) denaturing at 95 °C for 30 s, (3) annealing at 
55 °C for 1 min 15 s, (4) extension at 72 °C for 1 min, (5) extension at 72 °C for 30 min. Steps 
2–4 were cycled through 35 times.  
Fragment analysis was performed at the Institute for Molecular Medicine Finland (FIMM) 
Technology Centre. The fragments were run in an ABI3730xl electrophoresis run with a 
GeneScanTM-500 LIZ
® 
size standard (Applied Biosystems). All methods were performed 
according to manufacturers’ instructions.  
The fragment analysis graphs were analyzed by GeneMarker (SoftGenetics, State College, PA, 
version 1.4) software. Each tumor graph was compared to its corresponding normal graph to 
ensure the somatic origin of the observed changes. A length difference of one or more 
nucleotides between the tumor and normal graphs was considered significant.  
Ethics approval  
The study was approved by the Ethics Committee of the Hospital district of Helsinki and 
Uusimaa. All samples were derived either after an informed consent signed by the patient or 
authorization by the National Supervisory Authority for Welfare and Health.  
Results  
In this study, we analyzed the quasimonomorphic EWS16T locus in 157 MSI and 148 MSS 
Finnish CRCs, in 56 Danish MSI CRCs, and in their corresponding normal samples. 
Assessment of the EWS16T repeat length with fragment analysis revealed that from the initial 
set of 157 MSI CRCs, 156 tumors (99.4 %) showed shortening of the repeat length and only 
one tumor was wild type for the repeat (Table 1). Of the 157 tumors, 31 were from patients 
with Lynch syndrome. All the 148 MSS tumors were wild type for the locus.  
In the additional set of 56 Danish MSI CRCs, all tumors showed alterations in the repeat length; 
one tumor exhibited an insertion of one base whereas the other 55 tumors showed contraction 
of the repeat. Therefore, similar to the previous study and as is typical for MSI, instability was 
driven mostly by deletion rather than insertion [8].  
For the one MSI CRC that displayed two wild type alleles for the EWS16T tract, the Bethesda 
panel was redone to ensure the MSI status of the sample. The tumor exhibited instability in 
four of the five markers: BAT25, BAT26, D17S250, and D2S123. Exome sequencing data was 
available for this tumor, and it was scrutinized for mutations elsewhere in EWSR1 with negative 
results.  
Discussion  
EWS16T, a mononucleotide tract consisting of 16 thymines in the 3′-UTR of the EWSR1 gene, 
was recently reported to represent a novel, quasimonomorphic MSI target gene locus, which 
identifies both hereditary and sporadic MSI colorectal, gastric, and endometrial cancers with 
perfect sensitivity and specificity [8]. In our study, the repeat was analyzed by fragment 
analysis in altogether 213 MSI (157 Finnish and 56 Danish) and 148 MSS samples. The results 
showed nearly perfect sensitivity for MSI CRC both in the Finnish and Danish samples; the 
repeat was mutated in 156 out of the 157 Finnish and in all the 56 Danish MSI CRCs. All the 
148 MSS tumors tested were wild type for the locus. All the 156 mutations seen in the Finnish 
MSI CRCs were deletions and of the 56 mutated Danish MSI CRCs all but one showed a 
deletion. Our results thus support the previously reported finding [8].  
The MSI status of the Finnish tumor that was wild type for the EWS16T locus was confirmed 
as it showed instability in four of the five Bethesda panel markers. According to the 
pathologist’s evaluation, the tumor was a small adenocarcinoma classified as T2N0M0. One 
could speculate that perhaps the tumor was still in such early stage that EWS16T had simply 
not acquired mutations yet. On the other hand, instability in four out of the five markers of the 
Bethesda panel suggests that the tumor was already rather unstable. 
Exome sequencing data was available for this tumor, and it was scrutinized for mutations 
elsewhere in EWSR1 with negative results.  
A large number of genetic loci have been shown to be affected by MSI but the possible selective 
advantage of most such mutations is unclear [6]. EWSR1 is located at chromosome 22q12 and 
it encodes a nuclear protein consisting of 656 amino acids [13]. It is thought to be involved in 
a variety of cellular functions such as mitotic spindle formation, microtubule stabilization as 
well as DNA repair. The gene is also known to be involved in the development of Ewing 
sarcoma, the second most common bone malignancy in adolescents and young adults [14]. In 
85 % of Ewing sarcomas, EWSR1 has fused with FLI1 to form EWSR1–FLI1 that results from 
a translocation between chromosomes 22 and 11. Later, fusions of EWSR1 have been reported 
in many other sarcoma types such as myxoid liposarcomas and extraskeletal myxoid 
chondrosarcomas [13]. The deletions and insertions observed in the 16T/U-repeat occur in the 
3′-UTR of EWSR1 and therefore do not alter the coding sequence of the gene. The gene does, 
however, undergo alternative polyadenylation resulting in two transcripts of different length 
[15]. In the study by Kishore et al. higher expression for the longer isoform was observed in 
MSI CRC cell lines [8]. They also reported significant down regulation of protein levels 
associated with EWS16T tract deletions. In an immunohistochemical examination, Lynch 
syndrome patients were, interestingly, shown to exhibit diffuse cytoplasmic expression of the 
protein, whereas in sporadic MSI cancers the protein was expressed exclusively in the nucleus. 
Therefore, this protein was thought to play a role in the tumorigenesis of MSI CRC.  
Detection of MSI has important clinical implications as it can be used in guiding prognosis and 
therapeutic choices. MSI CRC has been linked to better prognosis as well as resistance to 
certain chemotherapeutics [2]. Also diagnosis of MSI is critical for identifying patients with 
Lynch syndrome that should potentially receive genetic counseling as well as clinical 
monitoring. Since 1992 when MSI was first described, a variety of methods have been 
established for determining the MSI status of tumors [2]. Several studies have shown different 
methods to be equally precise in identifying MSI [16,17]. Immunohistochemistry detects 
absence of protein expression and has been the first widely-used method for identifying MSI 
in tumors as MSI CRCs are known to show absence of protein expression in proteins of the 
MMR machinery such as MLH1 and MSH2 [17,18]. Hundreds of primer sequences have been 
published for amplification of different mono-, di-, tri-, and tetranucleotide repeats by PCR and 
several different methods have been used for their visualization [12,16]. In 1997, the National 
Cancer Institute hosted “The International Workshop on MSI and RER Phenotypes in Cancer 
Detection and Familial Predisposition” to review the field, and a panel of five markers, the so 
called Bethesda panel, was determined [7]. The panel consists of two mononucleotide markers 
(BAT25 and BAT26), and three dinucleotide markers (D5S346, D17S250, and D2S123) and 
is currently the most used method for DNA-based MMR determination in clinical use [19].  
Next generation sequencing (NGS) technologies are increasingly used in cancer genetics 
studies as well as in clinical diagnostics. Several recent studies have involved successful 
sequencing of tumors exhibiting MSI, and NGS has been reported to have high accuracy in 
detection of mutations targeting microsatellites [20–23]. Two studies have evaluated NGS to 
have high accuracy in MSI status determination [24,25]. NGS methods, however, are, costly 
and therefore not suitable for routine diagnostics at present. Due to the high accuracy of the 
EWS16T marker in determining MSI in both our study and in the study by Kishore et al. it 
seems that the marker might have the potential to replace the Bethesda panel in MSI diagnostics 
in routine practice [8]. Utilizing only one marker instead of a panel of five markers would 
reduce the costs of MSI diagnostics as well as manual work in the laboratory. A subsequent 
study comparing the sensitivity and specificity of the Beteshda panel and EWS16T in an 
extensive, uncharacterized set of CRCs would finally confirm the accuracy of this marker 
before adopting it in routine clinical practice.  
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Table 1. EWS16T instability in 213 microsatellite unstable colorectal cancers and 148 microsatellite stable 
colorectal cancers 
      
   EWES16T tract status 
Samples analyzed Number MSI status wt n (%) Contraction n (%) Expansion n (%) 
MSI colorectal cancers 213 MSI-high 1 (0.5) 212 (99.5) 1 (0.5) 
     Finnish 157 MSI-high 1 (0.6) 157 (100) 0 (0) 
     Danish 56 MSI-high 0 (0) 55 (98.2) 1 (1.7) 
      
MSS colorectal cancers      
     Finnish 148 MSS 148 0 0 
  
  
     
 
